Ad26.COV2.S — Competitive Intelligence Brief

Ad26.COV2.S (Ad26.COV2.S) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic

Target snapshot

Ad26.COV2.S (Ad26.COV2.S) — National Institute of Allergy and Infectious Diseases (NIAID). Ad26.COV2.S is a viral vector vaccine that delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate immune responses against COVID-19.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ad26.COV2.S TARGET	Ad26.COV2.S	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein
COMIRNATY intramuscular injection	comirnaty-intramuscular-injection	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
The Pfizer mRNA-based BNT162b2 vaccine	The Pfizer mRNA-based BNT162b2 vaccine	dafna yahav	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
Casirivimab and Imdevimab Drug Combination	Casirivimab and Imdevimab Drug Combination	Mansoura University Hospital	marketed	Monoclonal antibody combination (SARS-CoV-2 neutralizing antibodies)	SARS-CoV-2 spike protein receptor-binding domain
COVID-19 mRNA vaccine	COVID-19 mRNA vaccine	Vaccine Company, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation	mRNA-1273 Variant-containing Formulation	ModernaTX, Inc.	marketed	mRNA vaccine	SARS-CoV-2 spike protein (variant-specific)
Novavax recombinant protein vaccine	Novavax recombinant protein vaccine	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Recombinant protein vaccine	Viral surface antigens (e.g., SARS-CoV-2 spike protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
2. University of Oxford · 3 drugs in this class
3. Crucell Holland BV · 3 drugs in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
5. Bharat Biotech International Limited · 2 drugs in this class
6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
7. London School of Hygiene and Tropical Medicine · 1 drug in this class
8. Samia Hassan El-Shishtawy · 1 drug in this class
9. University Medicine Greifswald · 1 drug in this class
10. Aeras · 1 drug in this class